Protein kinases as therapeutic targets for Alzheimer’s disease: a brief review

Isabela Marie Fernandes Silva , Graziella dos Reis Rosa Franco , Vanessa Silva Gontijo , Claudio Viegas Jr.

Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (5) : 411 -441.

PDF (19643KB)
Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (5) :411 -441. DOI: 10.37349/ent.2024.00092
Review
research-article
Protein kinases as therapeutic targets for Alzheimer’s disease: a brief review
Author information +
History +
PDF (19643KB)

Abstract

Alzheimer’s disease (AD) is a progressive and incurable neurodegenerative disorder, with an unknown etiology and a multifactorial pathophysiology characterized by protein misfolding, neuroinflammation, and neuronal loss. There are three well-discussed main hypotheses for the pathophysiology of AD, which are related to i) the accumulation of amyloid β (Aβ) protein aggregates in the extracellular space, ii) deposition of hyperphosphorylated tau fragments as neurofibrillary tangles, and iii) dysregulation of hemostasis of some neurotransmitters involved in the disease, such as acetylcholine (ACh) and glutamate. The association of all these factors is responsible for installing oxidative stress and neuroinflammation, which contribute to progressive neuronal death in specific brain regions. More recently, other remarkable pathological characteristics have been described, involving changes in all levels of cellular components, especially in the action and function of protein kinases. These enzymes are crucial for cellular regulation since they play a pivotal role in the phosphorylation of protein substrates by transferring a phosphate group from the ATP molecule to threonine, serine, or tyrosine residues. In more recent studies, some kinases have been especially reported by their role in inflammatory and oxidative processes associated to AD, such as cAMP-dependent protein kinase A (PKA), cyclin-dependent protein kinase 5 (CDK5), glycogen synthase kinase 3β (GSK-3β), and the microtubule affinity regulatory kinases (MARKs). Under homeostatic conditions, protein kinases act as cellular signals, directing physiological responses, but in AD pathogenesis, these enzymes have an exacerbated activity in the brain, justifying the need for a better comprehension of their function and role, and how new kinase inhibitors could lead to innovative drugs. In this context, this brief review aimed to compile the literature data related to the most recent efforts and strategies in Medicinal Chemistry in the discovery of new kinase inhibitors, opening new ways to AD therapeutics.

Keywords

Kinase inhibitors / neurodegeneration / protein kinases / Alzheimer’s disease

Cite this article

Download citation ▾
Isabela Marie Fernandes Silva, Graziella dos Reis Rosa Franco, Vanessa Silva Gontijo, Claudio Viegas Jr.. Protein kinases as therapeutic targets for Alzheimer’s disease: a brief review. Exploration of Neuroprotective Therapy, 2024, 4 (5) : 411-441 DOI:10.37349/ent.2024.00092

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

De Falco A, Cukierman DS, Hauser-Davis RA, Rey NA. Alzheimer’s disease: etiological hypotheses and treatment perspectives. Quim Nova. 2016; 39: 63-80. Portuguese.

[2]

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7: 263-9.

[3]

Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011; 7: 137-52.

[4]

Rabinovici GD. Late-onset Alzheimer Disease. Continuum (Minneap Minn). 2019; 25: 14-33.

[5]

Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 2: a006239.

[6]

Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019; 179: 312-39.

[7]

Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021; 7: 33.

[8]

Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016; 12: 292-323.

[9]

Anwal L, Chandakavate S, Lalitha S, Thilagasundari MK. A comprehensive review on Alzheimer’s disease. World J Pharm Pharm Sci. 2021; 10: 1170-85.

[10]

Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules. 2020; 25: 5789.

[11]

Visweswaran V, Roshni PR. Role of Enzymes in Causing Neurological Disorders. Int J Res Pharm Sci. 2021; 12: 466-76.

[12]

Turab Naqvi AA, Hasan GM, Hassan MI. Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer’s Disease. Curr Top Med Chem. 2020; 20: 1059-73.

[13]

Silva BV, Horta BAC, de Alencastro RB, Pinto AC. Kinase protein: structural features and chemical inhibitors. Quim Nova. 2009; 32: 453-62. Portuguese.

[14]

Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov. 2007; 6: 464-79.

[15]

Šimić G, Babić Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, et al. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules. 2016; 6: 6.

[16]

Starkov AA, Beal FM. Portal to Alzheimer’s disease. Nat Med. 2008; 14: 1020-1.

[17]

What is Alzheimer’s Disease? [Internet]. Chicago: Alzheimer’s Association®; c2024 [cited 2024 Jul 10]. Available from: https://www.alz.org/alzheimers-dementia/what-is-alzheimers

[18]

Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003; 306: 821-7.

[19]

Sanabria-Castro A, Alvarado-Echeverría I, Monge-Bonilla C. Molecular Pathogenesis of Alzheimer’s Disease: An Update. Ann Neurosci. 2017; 24: 46-54.

[20]

Viegas FPD, Simões MCR, da Rocha MD, Castelli MR, Moreira MS, Viegas C Jr. Alzheimer’s Disease: Characterization, Evolution and Implications of the Neuroinflammatory Process. Rev Virtual Quim. 2011; 3: 286-306. Portuguese.

[21]

Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009; 11: 111-28.

[22]

Carreiras MC, Mendes E, Perry MJ, Francisco AP, Marco-Contelles J. The multifactorial nature of Alzheimer’s disease for developing potential therapeutics. Curr Top Med Chem. 2013; 13: 1745-70.

[23]

Cavalli A, Bolognesi ML, Capsoni S, Andrisano V, Bartolini M, Margotti E, et al. A small molecule targeting the multifactorial nature of Alzheimer’s disease. Angew Chem Int Ed Engl. 2007; 46: 3689-92.

[24]

Manssour Fraga CA, Barreiro EJ. New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs. Curr Drug Ther. 2008; 3: 1-13.

[25]

Dementia [Internet]. Geneva: World Health Organization; c2024 [cited 2024 Jul 10]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia

[26]

Nobre NC, Novais TS, dos Santos PACL, Lima EC, Malta EMR, de Pinho L. Medical practice for the management of dementias in the municipalities that are center of residency in family healthcare in Minas Gerais. Rev Bras Geriatr Gerontol. 2020; 23: e200280.

[27]

Matos DF, da Paz WS, de Sousa Santos ABA, Silva MA, de Oliveira SF, Leite CCB, et al. Epidemiological characterization of Alzheimer mortality in Brazil from 2010 to 2019. Res Soc Dev. 2021; 10:e74101119316.

[28]

Ayodele T, Rogaeva E, Kurup JT, Beecham G, Reitz C. Early-Onset Alzheimer’s Disease: What Is Missing in Research? Curr Neurol Neurosci Rep. 2021; 21: 4.

[29]

The stages of Alzheimer’s disease [Internet]. Alzheimer Society of Canada; c2024 [cited 2024 Mar 10]. Available from: https://alzheimer.ca/en/about-dementia/what-alzheimers-disease/stages-alzheimers-disease

[30]

Chen XQ, Mobley WC. Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species. Front Neurosci. 2019; 13: 659.

[31]

Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci. 2018; 19: 687-700.

[32]

Cai Z, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int J Neurosci. 2014; 124: 307-21.

[33]

Rojo LE, Fernández JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch Med Res. 2008; 39: 1-16.

[34]

Estes ML, McAllister AK. Alterations in immune cells and mediators in the brain: It’s not always neuroinflammation! Brain Pathol. 2014; 24: 623-30.

[35]

Reitz C. Alzheimer’s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis. 2016; 2016: 369808.

[36]

Armstrong RA. Risk factors for Alzheimer’s disease. Folia Neuropathol. 2019; 57: 87-105.

[37]

Balazs R. Epigenetic mechanisms in Alzheimer’s disease. Degener Neurol Neuromuscul Dis. 2014; 4: 85-102.

[38]

Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci. 2006; 7: 278-94.

[39]

Roda AR, Serra-Mir G, Montoliu-Gaya L, Tiessler L, Villegas S. Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease. Neural Regen Res. 2022; 17: 1666-74.

[40]

Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018; 14: 225-36.

[41]

Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Inflammation in Alzheimer’s disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol. 2009; 87: 181-94.

[42]

Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992; 256: 184-5.

[43]

Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015; 18: 794-9.

[44]

Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem. 2009; 110: 1129-34.

[45]

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016; 8: 595-608.

[46]

Mohamed T, Shakeri A, Rao PPN. Amyloid cascade in Alzheimer’s disease: Recent advances in medicinal chemistry. Eur J Med Chem. 2016; 113: 258-72.

[47]

Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides. 2015; 52: 1-18.

[48]

Bekdash RA. The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer’s Disease. Int J Mol Sci. 2021; 22: 1273.

[49]

Bukke VN, Archana M, Villani R, Romano AD, Wawrzyniak A, Balawender K, et al. The Dual Role of Glutamatergic Neurotransmission in Alzheimer’s Disease: From Pathophysiology to Pharmacotherapy. Int J Mol Sci. 2020; 21: 7452.

[50]

Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci U S A. 1991; 88: 7552-6.

[51]

Tabaton M, Piccini A. Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer’s disease. Int J Exp Pathol. 2005; 86: 139-45.

[52]

Luo JE, Li YM. Turning the tide on Alzheimer’s disease: modulation of γ-secretase. Cell Biosci. 2022; 12: 2.

[53]

Brion JP. Neurofibrillary tangles and Alzheimer’s disease. Eur Neurol. 1998; 40: 130-40.

[54]

Metaxas A, Kempf SJ. Neurofibrillary tangles in Alzheimer’s disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen Res. 2016; 11: 1579-81.

[55]

de Paula VJR, Guimarães FM, Forlenza OV. The role of TAU protein in the pathophysiology of frontotemporal dementia. Arch Clin Psychiatry. 2009; 36: 197-202. Portuguese.

[56]

Wei Y, Liu M, Wang D. The propagation mechanisms of extracellular tau in Alzheimer’s disease. J Neurol. 2022; 269: 1164-81.

[57]

Holtzman DM, Carrillo MC, Hendrix JA, Bain LJ, Catafau AM, Gault LM, et al. Tau: From research to clinical development. Alzheimers Dement. 2016; 12: 1033-9.

[58]

Verma M, Lizama BN, Chu CT. Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Transl Neurodegener. 2022; 11: 3.

[59]

Geldenhuys WJ, Leeper TC, Carroll RT. mitoNEET as a novel drug target for mitochondrial dysfunction. Drug Discov Today. 2014; 19: 1601-6.

[60]

Reddy PH. Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer’s disease. CNS Spectr. 2009; 14: 8-13.

[61]

Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018; 141: 1917-33.

[62]

Reale M, Costantini E. Cholinergic Modulation of the Immune System in Neuroinflammatory Diseases. Diseases. 2021; 9: 29.

[63]

FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment [Internet]. Silver Spring: FDA; [cited 2024 Jun 5]. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment

[64]

FDA’s Decision to Approve New Treatment for Alzheimer’s Disease [Internet]. Silver Spring: FDA; [cited 2024 Jul 10]. Available from: https://www.fda.gov/drugs/our-perspective/fdas-decision-approve-new-treatment-alzheimers-disease

[65]

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023; 388: 9-21.

[66]

Flicker L. Acetylcholinesterase inhibitors for Alzheimer’s disease. BMJ. 19996; 318: 615-6.

[67]

Walczak-Nowicka ŁJ, Herbet M. Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis. Int J Mol Sci. 2021; 22: 9290.

[68]

Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer’s disease. Int J Alzheimers Dis. 2016; 2016: 728983.

[69]

Zemek F, Drtinova L, Nepovimova E, Sepsova V, Korabecny J, Klimes J, et al. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf. 2014; 13: 759-74.

[70]

Singh M, Kaur M, Kukreja H, Chugh R, Silakari O, Singh D. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur J Med Chem. 2013; 70: 165-88.

[71]

Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology. 2021; 190: 108352.

[72]

Witt A, Macdonald N, Kirkpatrick P. Memantine hydrochloride. Nat Rev Drug Discov. 2004; 3: 109-10.

[73]

Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003; 348: 1333-41.

[74]

Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res. 2013; 24: 358-69.

[75]

Beshir SA, Aadithsoorya AM, Parveen A, Goh SSL, Hussain N, Menon VB. Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review. Int J Alzheimers Dis. 2016; 2016: 9343514.

[76]

Day GS, Scarmeas N, Dubinsky R, Coerver K, Mostacero A, West B, et al. Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee. Neurology. 2022; 98: 619-31.

[77]

Yang P, Sun F. Aducanumab: The first targeted Alzheimer’s therapy. Drug Discov Ther. 2021; 15: 166-8.

[78]

Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2021; 8: 398-410.

[79]

Alexander GC, Knopman DS, Emerson SS, Ovbiagele B, Kryscio RJ, Perlmutter JS, et al. Revisiting FDA Approval of Aducanumab. N Engl J Med. 2021; 385: 769-71.

[80]

Aducanumab para Alzheimer [Internet]. Rio de Janeiro: Sociedade Brasileira de Geriatria e Gerontologia; [cited 2024 Mar 10]. Available from: https://sbgg.org.br/aducanumab-para-alzheimer/#:~:text=A%20nova%20droga%20%C3%A9%20destinada,%C3%A9%20a%20prote%C3%ADna%20beta%2Damil%C3%B3ide

[81]

Carta ABN para a Agência Nacional de Vigilância Sanitária [Internet]. São Paulo: Academia Brasileira de Neurologia; [cited 2024 Mar 10]. Available from: https://abneuro.org.br/2022/01/31/%EF%B F%BCcarta-abn-para-a-agencia-nacional-de-vigilancia-sanitaria/

[82]

Reardon S. FDA approves Alzheimer’s drug lecanemab amid safety concerns. Nature. 2023; 613: 227-8.

[83]

Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in Early Alzheimer’s Disease. N Engl J Med. 2021; 384: 1691-704.

[84]

Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimers Dement (N Y). 2021; 7: e12112.

[85]

Rashad A, Rasool A, Shaheryar M, Sarfraz A, Sarfraz Z, Robles-Velasco K, et al. Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials. Healthcare (Basel). 2022; 11: 32.

[86]

Yadav S, Mathur P. Orthosteric and allosteric modulation of human kinases: A mechanistic view. Front Biosci (Landmark Ed). 2020; 25: 1462-87.

[87]

Leroy K, Menu R, Conreur JL, Dayanandan R, Lovestone S, Anderton BH, et al. The function of the microtubule-associated protein tau is variably modulated by graded changes in glycogen synthase kinase-3beta activity. FEBS Lett. 2000; 465: 34-8.

[88]

Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, et al. Tau protein kinases: involvement in Alzheimer’s disease. Ageing Res Rev. 2013; 12: 289-309.

[89]

Taalab YM, Ibrahim N, Maher A, Hassan M, Mohamed W, Moustafa AA, et al. Mechanisms of disordered neurodegenerative function: concepts and facts about the different roles of the protein kinase RNA-like endoplasmic reticulum kinase (PERK). Rev Neurosci. 2018; 29: 387-415.

[90]

Murray AJ. Pharmacological PKA inhibition: all may not be what it seems. Sci Signal. 2008; 1: re4.

[91]

Vitolo OV, Sant’Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A. 2002; 99: 13217-21.

[92]

Sharma VK, Singh TG. CREB: A Multifaceted Target for Alzheimer’s Disease. Curr Alzheimer Res. 2020; 17: 1280-93.

[93]

Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, et al. PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett. 2006; 580: 6269-74.

[94]

Carlyle BC, Nairn AC, Wang M, Yang Y, Jin LE, Simen AA, et al. cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex. Proc Natl Acad Sci U S A. 2014; 111: 5036-41.

[95]

Bae HJ, Sowndhararajan K, Park HB, Kim SY, Kim S, Kim DH, et al. Danshensu attenuates scopolamine and amyloid-β-induced cognitive impairments through the activation of PKA-CREB signaling in mice. Neurochem Int. 2019; 131: 104537.

[96]

Cui SY, Yang MX, Zhang YH, Zheng V, Zhang HT, Gurney ME, et al. Protection from Amyloid β Peptide-Induced Memory, Biochemical, and Morphological Deficits by a Phosphodiesterase-4D Allosteric Inhibitor. J Pharmacol Exp Ther. 2019; 371: 250-9.

[97]

Liu SL, Wang C, Jiang T, Tan L, Xing A, Yu JT. The Role of Cdk5 in Alzheimer’s Disease. Mol Neurobiol. 2016; 53: 4328-42.

[98]

Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999; 402: 615-22.

[99]

Sharma S, Sicinski P. A kinase of many talents: non-neuronal functions of CDK5 in development and disease. Open Biol. 2020; 10: 190287.

[100]

Maitra S, Vincent B. Cdk5-p25 as a key element linking amyloid and tau pathologies in Alzheimer’s disease: Mechanisms and possible therapeutic interventions. Life Sci. 2022; 308: 120986.

[101]

Umfress A, Singh S, Ryan KJ, Chakraborti A, Plattner F, Sonawane Y, et al. Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior. Front Pharmacol. 2022; 13: 863762.

[102]

Liu B, Huang B, Liu J, Shi JS. Dendrobium nobile Lindl alkaloid and metformin ameliorate cognitive dysfunction in senescence-accelerated mice via suppression of endoplasmic reticulum stress. Brain Res. 2020; 1741: 146871.

[103]

Nie J, Tian Y, Zhang Y, Lu YL, Li LS, Shi JS. Dendrobium alkaloids prevent Aβ25-35-induced neuronal and synaptic loss via promoting neurotrophic factors expression in mice. PeerJ. 2016; 4: e2739.

[104]

Dubey T, Gorantla NV, Chandrashekara KT, Chinnathambi S. Photodynamic exposure of Rose-Bengal inhibits Tau aggregation and modulates cytoskeletal network in neuronal cells. Sci Rep. 2020; 10: 12380.

[105]

Mou CY, Xie YF, Wei JX, Wang QY, Le JY, Bao YJ, et al. Rose Bengal inhibits β-amyloid oligomers-induced tau hyperphosphorylation via acting on Akt and CDK5 kinases. Psychopharmacology (Berl). 2022; 239: 3579-93.

[106]

Loidreau Y, Dubouilh-Benard C, Nourrisson M, Loaëc N, Meijer L, Besson T, et al. Exploring Kinase Inhibition Properties of 9 H-pyrimido[5,4- b]- and [4,5- b]indol-4-amine Derivatives. Pharmaceuticals (Basel). 2020; 13: 89.

[107]

Schittek B, Sinnberg T. Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis. Mol Cancer. 2014; 13: 231.

[108]

Yang Y, Fan X, Liu Y, Ye D, Liu C, Yang H, et al. Function and inhibition of DYRK1A: Emerging roles of treating multiple human diseases. Biochem Pharmacol. 2023; 212: 115521.

[109]

Lee SJ, Chung YH, Joo KM, Lim HC, Jeon GS, Kim D, et al. Age-related changes in glycogen synthase kinase 3beta (GSK3beta) immunoreactivity in the central nervous system of rats. Neurosci Lett. 2006; 409: 134-9.

[110]

Lauretti E, Dincer O, Praticò D. Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochim Biophys Acta Mol Cell Res. 2020; 1867: 118664.

[111]

Cormier KW, Woodgett JR. Recent advances in understanding the cellular roles of GSK-3. F1000Res. 2017; 6: F1000 Faculty Rev-167.

[112]

Frizzo ME. Putative role of glycogen as a peripheral biomarker of GSK3β activity. Med Hypotheses. 2013; 81: 376-8.

[113]

Avila J, Wandosell F, Hernández F. Role of glycogen synthase kinase-3 in Alzheimer’s disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev Neurother. 2010; 10: 703-10.

[114]

Demuro S, Di Martino RMC, Ortega JA, Cavalli A. GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways. Int J Mol Sci. 2021; 22: 9098.

[115]

Chen CH, Zhou W, Liu S, Deng Y, Cai F, Tone M, et al. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol. 2012; 15: 77-90.

[116]

Ly PTT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, et al. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest. 2013; 123: 224-35.

[117]

Silva GM, Borges RS, Santos KLB, Federico LB, Francischini IAG, Gomes SQ, et al. Revisiting the Proposition of Binding Pockets and Bioactive Poses for GSK-3β Allosteric Modulators Addressed to Neurodegenerative Diseases. Int J Mol Sci. 2021; 22: 8252.

[118]

Llorach-Pares L, Rodriguez-Urgelles E, Nonell-Canals A, Alberch J, Avila C, Sanchez-Martinez M, et al. Meridianins and Lignarenone B as Potential GSK3β Inhibitors and Inductors of Structural Neuronal Plasticity. Biomolecules. 2020; 10: 639.

[119]

Han KM, Kang RJ, Jeon H, Lee HJ, Lee JS, Park H, et al. Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD. Cells. 2020; 9: 1655.

[120]

Yan N, Xie F, Tang LQ, Wang DF, Li X, Liu C, et al. Synthesis and biological evaluation of thieno[3,2-c]pyrazol-3-amine derivatives as potent glycogen synthase kinase 3β inhibitors for Alzheimer’s disease. Bioorg Chem. 2023; 138: 106663.

[121]

Chen H, Yu C, Liu W, Zhu C, Jiang X, Xu C, et al. Discovery of novel α-carboline derivatives as glycogen synthase kinase-3β inhibitors for the treatment of Alzheimer’s disease. Arch Pharm (Weinheim). 2022; 355: e2200156.

[122]

Liu W, Liu X, Tian L, Gao Y, Liu W, Chen H, et al. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer’s disease. Eur J Med Chem. 2021; 222: 113554.

[123]

Kumar Jain A, Gupta A, Karthikeyan C, Trivedi P, Dutt Konar A. Unravelling the Selectivity of 6,7-Dimethyl Quinoxaline Analogs for Kinase Inhibition: An Insight towards the Development of Alzheimer’s Therapeutics. Chem Biodivers. 2021; 18: e2100364.

[124]

Hu S, Xian Y, Fan Y, Mak S, Wang J, Tang J, et al. Significant combination of Aβ aggregation inhibitory and neuroprotective properties in silico, in vitro and in vivo by bis(propyl)-cognitin, a multifunctional anti-Alzheimer’s agent. Eur J Pharmacol. 2020; 876: 173065.

[125]

Liang Z, Li QX. Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3β Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New C-Glycosylflavones. ACS Chem Neurosci. 2018; 9: 1166-83.

[126]

Zhang D, Liu L, Pang L, Jin Q, Ke K, Hu M, et al. Biological evaluation and energetic analyses of novel GSK-3β inhibitors. J Cell Biochem. 2018; 119: 3510-8.

[127]

Ivasiv V, Albertini C, Gonçalves AE, Rossi M, Bolognesi ML. Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases. Curr Top Med Chem. 2019; 19: 1694-711.

[128]

Kumar A, Rohila Y, Kumar V, Lal K. A Mini Review on Pharmacological Significance of Isatin-1,2,3-Triazole Hybrids. Curr Top Med Chem. 2023; 23: 833-47.

[129]

Viegas-Junior C, Danuello A, Bolzani VdS, Barreiro EJ, Fraga CAM. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem. 2007; 14: 1829-52.

[130]

Dias KST, Viegas C Jr. Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease. Curr Neuropharmacol. 2014; 12: 239-55.

[131]

Gontijo VS, Viegas FPD, Ortiz CJC, de Freitas Silva M, Damasio CM, Rosa MC, et al. Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases. Curr Neuropharmacol. 2020; 18: 348-407.

[132]

Singh M, Kaur M, Chadha N, Silakari O. Hybrids: a new paradigm to treat Alzheimer’s disease. Mol Divers. 2016; 20: 271-97.

[133]

Nepali K, Sharma S, Sharma M, Bedi PMS, Dhar KL. Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids. Eur J Med Chem. 2014; 77: 422-87.

[134]

Ortiz CJC, de Freitas Silva M, Gontijo VS, Viegas FPD, Dias KST, Viegas C. Design of multi-target directed ligands as a modern approach for the development of innovative drug candidates for Alzheimer’s disease. In: Roy K, editor. Methods in Pharmacology and Toxicology. New York: Humana Press; 2019. pp. 255-351.

[135]

Viegas FPD, Gontijo VS, de Freitas Silva M, Ortiz CJC, Dos Reis Rosa Franco G, Ernesto JT, et al. Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents. Curr Neuropharmacol. 2022; 20: 1297-328.

[136]

Ortiz CJC, Damasio CM, Pruccoli L, Nadur NF, de Azevedo LL, Guedes IA, et al. Cinnamoyl- N-Acylhydrazone-Donepezil Hybrids: Synthesis and Evaluation of Novel Multifunctional Ligands Against Neurodegenerative Diseases. Neurochem Res. 2020; 45: 3003-20.

[137]

de Freitas Silva M, Tardelli Lima E, Pruccoli L, Castro NG, Guimarães MJR, da Silva FMR, et al. Design, Synthesis and Biological Evaluation of Novel Triazole N-acylhydrazone Hybrids for Alzheimer’s Disease. Molecules. 2020; 25: 3165.

[138]

Dias Viegas FP, de Freitas Silva M, Divino da Rocha M, Castelli MR, Riquiel MM, Machado RP, et al. Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates. Eur J Med Chem. 2018; 147: 48-65.

[139]

Prati F, Bottegoni G, Bolognesi ML, Cavalli A. BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer’s Disease. J Med Chem. 2018; 61: 619-37.

[140]

Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, et al. Multifunctional tacrine derivatives in Alzheimer’s disease. Curr Top Med Chem. 2013; 13: 1771-86.

[141]

Prati F, Bergamini C, Fato R, Soukup O, Korabecny J, Andrisano V, et al. Novel 8-Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer’s Disease. ChemMedChem. 2016; 11: 1284-95.

[142]

Perone R, Albertini C, Uliassi E, Di Pietri F, de Sena Murteira Pinheiro P, Petralla S, et al. Turning Donepezil into a Multi-Target-Directed Ligand through a Merging Strategy. ChemMedChem. 2021; 16: 187-98.

[143]

Lavayen BP, Yang C, Larochelle J, Liu L, Tishko RJ, de Oliveira ACP, et al. Neuroprotection by the cannabidiol aminoquinone VCE-004.8 in experimental ischemic stroke in mice. Neurochem Int. 2023; 165: 105508.

[144]

Pérez-Areales FJ, Garrido M, Aso E, Bartolini M, De Simone A, Espargaró A, et al. Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6. J Med Chem. 2020; 63: 9360-90.

[145]

Elkamhawy A, Woo J, Gouda NA, Kim J, Nada H, Roh EJ, et al. Melatonin Analogues Potently Inhibit MAO-B and Protect PC12 Cells against Oxidative Stress. Antioxidants (Basel). 2021; 10: 1604.

[146]

Mathew B, Oh JM, Baty RS, Batiha GE, Parambi DGT, Gambacorta N, et al. Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders. Environ Sci Pollut Res Int. 2021; 28: 38855-66.

[147]

Elkamhawy A, Kim HJ, Elsherbeny MH, Paik S, Park JH, Gotina L, et al. Discovery of 3,4-dichloro- N-(1 H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action. Bioorg Chem. 2021; 116: 105352.

[148]

Yao H, Uras G, Zhang P, Xu S, Yin Y, Liu J, et al. Discovery of Novel Tacrine-Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer’s Disease. J Med Chem. 2021; 64: 7483-506.

[149]

Jiang X, Zhou J, Wang Y, Chen L, Duan Y, Huang J, et al. Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer’s disease. Eur J Med Chem. 2020; 207: 112751.

[150]

Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, et al. Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3. Eur J Med Chem. 2019; 168: 58-77.

[151]

Sivaprakasam P, Han X, Civiello RL, Jacutin-Porte S, Kish K, Pokross M, et al. Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core. Bioorg Med Chem Lett. 2015; 25: 1856-63.

[152]

Shi XL, Wu JD, Liu P, Liu ZP. Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer’s disease. Eur J Med Chem. 2019; 167: 211-25.

[153]

Jiang X, Liu C, Zou M, Xie H, Lin T, Lyu W, et al. Discovery of 2-(cyclopropanecarboxamido)- N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer’s disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine. Eur J Med Chem. 2021; 223: 113663.

[154]

Jiang X, Wang Y, Liu C, Xing C, Wang Y, Lyu W, et al. Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer’s disease. Bioorg Med Chem. 2021; 30: 115940.

[155]

Ismaili L, Monnin J, Etievant A, Arribas RL, Viejo L, Refouvelet B, et al. (±)-BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer’s Disease. ACS Chem Neurosci. 2021; 12: 1328-42.

[156]

Annadurai N, Agrawal K, Džubák P, Hajdúch M, Das V. Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer’s disease. Cell Mol Life Sci. 2017; 74: 4159-69.

[157]

Matenia D, Mandelkow EM. The tau of MARK: a polarized view of the cytoskeleton. Trends Biochem Sci. 2009; 34: 332-42.

[158]

Voura M, Khan P, Thysiadis S, Katsamakas S, Queen A, Hasan GM, et al. Probing the Inhibition of Microtubule Affinity Regulating Kinase 4 by N-Substituted Acridones. Sci Rep. 2019; 9: 1676.

[159]

Shamsi A, Anwar S, Mohammad T, Alajmi MF, Hussain A, Rehman MT, et al. MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer’s Disease Therapy. Biomolecules. 2020; 10: 789.

[160]

Alrouji M, DasGupta D, Ashraf GM, Bilgrami AL, Alhumaydhi FA, Al Abdulmonem W, et al. Inhibition of microtubule affinity regulating kinase 4 by an acetylcholinesterase inhibitor, Huperzine A: Computational and experimental approaches. Int J Biol Macromol. 2023; 235: 123831.

[161]

Hruba L, Polishchuk P, Das V, Hajduch M, Dzubak P. An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry. Biomed Pharmacother. 2022; 146: 112549.

PDF (19643KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉